Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Advanced NSCLC with Performance Status 2
NCT00087412Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Median Survival up to 3 years. Started Sep 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00087412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087412.